What is the current Human Insulin market size?

The Human Insulin market size is approximately USD 43.6 billion as of 2022.

What is the expected growth forecast for the Human Insulin market?

The market is expected to grow at a CAGR of 4.8% from 2023 to 2028.

What are the key drivers of the Human Insulin market?

Increasing diabetes prevalence and rising demand for insulin analogs drive the market.

What are the major challenges facing the Human Insulin market?

High development costs and stringent regulatory requirements pose significant challenges.

Which regions are the leaders in the Human Insulin market?

North America and Europe are the leading regions due to high diabetes prevalence.

Who are the top companies in the Human Insulin market?

Eli Lilly, Novo Nordisk, and Sanofi are the leading companies in the market.

What future opportunities exist in the Human Insulin market?

Emerging markets and innovative delivery systems offer significant future outlook.

How does technology impact the Human Insulin market?

Advances in insulin pumps and pens improve treatment outcomes and drive market growth.

What is the current regulatory landscape for the Human Insulin market?

Stringent FDA and EMA regulations ensure high-quality products and patient safety.

Human Insulin Market Growth Drivers & Forecast 2033

Human Insulin by Application (Short Acting, Intermediate Acting, Long Acting, Pre-Mix Insulin), by Types (Insulin Analogs and Biosimilars, Human Insulin Biologics), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Human Insulin Market Size | CAGR 8.2 Forecast 2033

Human Insulin Market Growth Drivers & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Human Insulin Market Overview

The Human Insulin market refers to the global market for insulin products used to treat diabetes. As the diabetes prevalence continues to rise, the Human Insulin market size is estimated to be approximately $43.6 billion in 2025. The growth outlook for the Human Insulin market is promising, with a market forecast indicating a compound annual growth rate (CAGR) of around 4.5% from 2026 to 2033. This industry expansion is driven by macro drivers such as an increasing diabetic population, advances in insulin technology, and growing demand for biosimilar insulins. The scope of the Human Insulin market encompasses various types of insulin products, including rapid-acting, short-acting, intermediate-acting, and long-acting insulins, as well as their applications in treating type 1 and type 2 diabetes.

Loading chart…

Key forces shaping the Human Insulin industry include technology shifts towards more efficient and convenient insulin delivery systems, regulations supporting the development of biosimilar insulins, and changing consumer behavior driven by increasing awareness of diabetes management. The largest region for the Human Insulin market is North America, while the fastest-growing region is expected to be the Asia-Pacific region. The Human Insulin market is expected to experience significant growth in the forecast period, driven by these key forces and the increasing prevalence of diabetes worldwide.

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	23.19 billion
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	B. Braun; Becton, Dickinson; Biocon; Biodel; ELI Lilly; Julphar; NOVO Nordisk; Sanofi; Wockhardt; Ypsomed
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Human Insulin market is poised for significant growth, driven by factors such as increasing diabetes prevalence and advancements in insulin therapy. The Human Insulin market size is expected to expand substantially, with a promising growth forecast, driven by the rising demand for human insulin analogs and biosimilars.

Growth Drivers2 items

Increasing global diabetes prevalence, particularly in emerging economies, is driving the demand for human insulin, thereby contributing to the growth of the Human Insulin market size

Advances in recombinant DNA technology have enabled the development of more effective and safer human insulin analogs, further fueling the growth forecast of the Human Insulin market

Restraints2 items

High research and development costs associated with human insulin analogs and biosimilars may hinder the growth of the Human Insulin market, impacting the overall Human Insulin market size

Stringent regulatory requirements and patent protection for human insulin products may limit the entry of new players, affecting the growth forecast of the Human Insulin market

Opportunities2 items

The growing demand for Biosimilars and generic human insulin products in emerging economies presents significant opportunities for manufacturers to expand their market share and contribute to the Human Insulin market size

Increasing investment in research and development to improve human insulin formulations and delivery systems may lead to innovative products and therapies, driving the growth forecast of the Human Insulin market

Challenges2 items

Managing the complex supply chain and ensuring a stable supply of high-quality human insulin products is a significant challenge for manufacturers, which may impact the Human Insulin market size and growth forecast

The Human Insulin market is subject to intense competition and pricing pressure, which may affect the profitability of manufacturers and influence the overall Human Insulin market dynamics

Market Segmentation

Loading chart…

The Human Insulin market can be segmented based on Application, which includes Type 1 Diabetes and Type 2 Diabetes. This segmentation is crucial in understanding the Human Insulin segmentation as it allows manufacturers to tailor their products to specific patient needs, ultimately contributing to the overall market size. For instance, Type 1 Diabetes accounts for a significant share of the market, driven by the increasing prevalence of the condition among the younger population.

Another significant segmentation category in the Human Insulin market is Types, which includes Rapid-acting, Short-acting, Intermediate-acting, and Long-acting insulin. Each subtype has its unique characteristics, such as duration of action and onset of action, catering to diverse patient requirements. The Long-acting insulin subtype, for example, has gained popularity due to its convenience and reduced risk of hypoglycemia, thereby driving the market growth. Understanding these subtypes is essential for market players to develop targeted strategies and capitalize on emerging opportunities in the Human Insulin market.

Human Insulin Segmentation Breakdown8 items

Application

Short Acting

Intermediate Acting

Long Acting

Pre-Mix Insulin

Types

Insulin Analogs and Biosimilars

Human Insulin Biologics

Regional Insights

Loading chart…

The Human Insulin market growth is expected to vary across regions, with the Asia Pacific region being the largest, accounting for approximately 40% of the global market, and also the fastest-growing region, driven by increasing adoption of human insulin, favorable policies, and significant investments in healthcare infrastructure. Key drivers for this region include a large diabetic population, rising demographics, and improving ecosystem maturity.

In North America, key drivers include a well-established infrastructure, high adoption rates of advanced insulin products, and a strong ecosystem. Europe is driven by favorable policies, a high prevalence of diabetes, and significant investments in research and development. Latin America's growth is driven by increasing adoption and improving infrastructure, while the Middle East & Africa region is driven by rising demographics and growing investments in healthcare.

The regional forecast indicates that the Asia Pacific region will continue to dominate the Human Insulin market growth, driven by its large and growing population, increasing adoption of human insulin, and significant investments in healthcare. As the global Human Insulin market continues to evolve, understanding the key drivers and trends in each region will be crucial for stakeholders to make informed decisions and capitalize on emerging opportunities.

Competitive Landscape

The Human Insulin market is moderately consolidated, driven by a mix of global players and local companies. The Human Insulin competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players focus on product innovation and regulatory approvals, while local companies emphasize pricing and distribution.

Companies employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. Key players in the market include:

B. Braun: regional expansion

Becton, Dickinson: innovation pipeline

Biocon: local manufacturing

ELI Lilly: premium pricing

NOVO Nordisk: vertical integration

Sanofi: OEM tie-ups

Key Human Insulin Companies10 items

B. Braun

Becton, Dickinson

Biocon

Biodel

ELI Lilly

Julphar

NOVO Nordisk

Sanofi

Wockhardt

Ypsomed

Market Ecosystem

The Human Insulin ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, suppliers, integrators, channels, and end users. Value is created and captured through the development, manufacturing, and distribution of human insulin products, with various participants contributing to the overall Human Insulin ecosystem. The boundaries of this ecosystem are defined by the interactions between these participants, from raw material suppliers to end users, and the flow of value through the value chain analysis.

Raw material suppliers — provide insulin precursors

OEMs / manufacturers — produce human insulin products

Technology providers — develop insulin delivery systems

Distributors / channel partners — facilitate product distribution

Service providers / after-sales — offer support and maintenance

End users / buyers — purchase and administer human insulin

Regulators/standards bodies — oversee safety and efficacy standards

The flow of value in the Human Insulin ecosystem is influenced by various control points, including regulatory approvals and standards. Dependency risks, such as input constraints and approvals, can impact the supply chain, while switching costs and partnerships can affect the adoption of new products. The ecosystem differs by region, with varying regulatory requirements and market dynamics. Understanding these factors is crucial for navigating the complex Human Insulin ecosystem and identifying opportunities for growth and innovation.

Recent Industry Insights

The Human Insulin market has witnessed significant developments over the last 12-18 months, shaping the future of Human Insulin industry trends. Recent partnerships between major pharmaceutical companies have led to the creation of innovative insulin products, enhancing the treatment of diabetes. Notable mergers and acquisitions have also been observed, resulting in the expansion of product portfolios and increased market share. Furthermore, several product launches have taken place, incorporating advanced technologies to improve insulin delivery systems. Regulatory changes have also played a crucial role, with updates in guidelines and policies influencing the development and approval of new insulin products. Additionally, a shift in consumer trends towards more personalized and convenient treatment options has been observed, driving the demand for innovative insulin products.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Human Insulin market. The market attractiveness is moderate, driven by increasing demand for diabetes management solutions. The competitive intensity is high, with key players investing in research and development to improve efficacy and safety. The long-term outlook for the Human Insulin market outlook is positive, with a growing patient population and ongoing innovation in insulin therapies. However, the demand–supply balance may be affected by regulatory changes and manufacturing capacity constraints. Key risk factors include pricing pressure and supply chain disruptions.

11 items

1. Executive Summary

2. Human Insulin Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Human Insulin Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Human Insulin Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Short Acting

6.1.2. Intermediate Acting

6.1.3. Long Acting

6.1.4. Pre-Mix Insulin

6.2. Global Human Insulin Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Insulin Analogs and Biosimilars

6.2.2. Human Insulin Biologics

6.3. Global Human Insulin Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Human Insulin Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Human Insulin Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Human Insulin Market Competition by Key Manufacturers

8.1. Global Human Insulin Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Human Insulin: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. B. Braun

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Becton, Dickinson

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Biocon

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Biodel

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. ELI Lilly

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Julphar

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. NOVO Nordisk

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Sanofi

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Wockhardt

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Ypsomed

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Human Insulin Market

Figure 4: Global Human Insulin Market: Drivers

Figure 5: Global Human Insulin Market: Challenges

Figure 6: Global Human Insulin Market: Trends

Figure 7: Global Human Insulin Market: Opportunity

Figure 8: Global Human Insulin Market: Restraint

Figure 9: Global Human Insulin Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Human Insulin Market Value (USD Million) By Region

Figure 15: Global Human Insulin Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Human Insulin Market Value (USD Million) By Region

Figure 23: Global Human Insulin Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Human Insulin Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Human Insulin Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Human Insulin Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Human Insulin Market Value (USD Million) By Region

Table 10: Global Human Insulin Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Human Insulin Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Human Insulin Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Human Insulin Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: B. Braun Basic Information And Sales Area

Table 31: B. Braun. Products Portfolio

Table 32: Becton, Dickinson Basic Information And Sales Area

Table 33: Becton, Dickinson. Products Portfolio

Table 34: Biocon Basic Information And Sales Area

Table 35: Biocon. Products Portfolio

Table 36: Biodel Basic Information And Sales Area

Table 37: Biodel. Products Portfolio

Table 38: ELI Lilly Basic Information And Sales Area

Table 39: ELI Lilly. Products Portfolio

Table 40: Julphar Basic Information And Sales Area

Table 41: Julphar. Products Portfolio

Table 42: NOVO Nordisk Basic Information And Sales Area

Table 43: NOVO Nordisk. Products Portfolio

Table 44: Sanofi Basic Information And Sales Area

Table 45: Sanofi. Products Portfolio

Table 46: Wockhardt Basic Information And Sales Area

Table 47: Wockhardt. Products Portfolio

Table 48: Ypsomed Basic Information And Sales Area

Table 49: Ypsomed. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global Human Insulin Market Value (USD Million) By Region

Table 55: Global Human Insulin Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Human Insulin Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	23.19 billion
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	B. Braun; Becton, Dickinson; Biocon; Biodel; ELI Lilly; Julphar; NOVO Nordisk; Sanofi; Wockhardt; Ypsomed
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options